May 11, 2022 / 07:40PM GMT
Derik De Bruin - BofA Securities, Research Division - MD of Equity Research
Welcome to Bank of America's 2022 Healthcare Conference live from Las Vegas. I'm Derik De Bruin, the senior life sciences and diagnostic tools analyst, also CROs and CMOs. Our next company is Catalent. And with us on Catalent is Tom Castellano, CFO; and Paul Surdez, Head of IR. Gentlemen, thank you for being here. Thanks for making the trip out to Vegas. We've grown up together. We participated in your IPO in 2014. What a difference a 9 year makes -- 8 years. I can't even count anymore. Company was 3% biotech when we did the IPO. It's 50-plus percent now.
Margins were hardly moving. Margins are now really expanding. I mean it's been a really interesting story. I think I'll let you kick it off, Tom, like a recap what's going on, and then I'm going to pepper you with a bunch of questions.
Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO
Yes. No, thanks, Derik. Appreciate the opportunity, and thanks, everyone, for joining. The other thing I'd highlight around the IPO is
Catalent Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers